USP Launches Trust Accelerated Program to Speed Development of COVID-19 Treatments and Vaccines
May 14, 2020
Tags:
To accelerate the development of safe and effective COVID-19 vaccines, medicines and other treatments, the U.S. Pharmacopeia (USP) has launched a new program to support scientists, developers and manufacturers worldwide.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.
.svg)
